Orexigen has announced that the company is on the cusp of having enough cardiovascular data from its Light Study on the anti-obesity pill Contrave for a possible resubmission for a new drug application to the FDA by the end of the year.
http://seekingalpha.com/article/1659192-orexigen-readies-new-drug-application?source=feed
http://seekingalpha.com/article/1659192-orexigen-readies-new-drug-application?source=feed
No comments:
Post a Comment